Will the Phase 2 trial "PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY" reach primary completion on or before May 30, 2027?

Resolves Yes if ClinicalTrials.gov record NCT06354140 (Daping Hospital and the Research Institute of Surgery of the Third Military Medical University) shows an actual primary completion date on or before May 30, 2027. Registered date at generation: May 30, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By May 30, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.